Intellia Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell NTLA and other ETFs, options, and stocks.About NTLA
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.
CEOJohn M. Leonard
CEOJohn M. Leonard
Employees403
Employees403
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2014
Founded2014
Employees403
Employees403
NTLA Key Statistics
Market cap1.27B
Market cap1.27B
Price-Earnings ratio-2.52
Price-Earnings ratio-2.52
Dividend yield—
Dividend yield—
Average volume3.85M
Average volume3.85M
High today$12.30
High today$12.30
Low today$11.74
Low today$11.74
Open price$12.27
Open price$12.27
Volume3.63M
Volume3.63M
52 Week high$23.76
52 Week high$23.76
52 Week low$5.90
52 Week low$5.90
NTLA News
TipRanks 4d
Cathie Wood’s ARK Investment buys 131.7K shares of Intellia Therapeutics today20:04 EDT Cathie Wood’s ARK Investment buys 131.7K shares of Intellia Therapeutics (NTLA) today Published first on TheFly – the ultimate source for real-time,...
Analyst ratings
78%
of 27 ratingsBuy
77.8%
Hold
18.5%
Sell
3.7%
People also own
Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.